Want to see AU:NOX full AI Analyst Report?
Top Page
Noxopharm Ltd.
(Sydney:NOX)
Select Model
Select Model
Rating:50Neutral
Price Target:
AU$0.08
▼(-12.22% Downside)
Action:Reiterated
Date:06/25/26
The score is held down primarily by weak financial performance—significant ongoing losses, continued cash burn, and a weaker 2025 balance sheet with higher leverage. Technicals are supportive (price above key moving averages with positive MACD), but valuation is constrained by negative earnings and no dividend support.
Positive Factors
Focused oncology R&D pipeline
A focused oncology R&D strategy targeting radiotherapy enhancement is a durable business-model strength: it concentrates scientific expertise, can create high barriers to entry, and aligns with enduring unmet needs in cancer care. Success can yield licensing, partnerships and durable revenue streams if clinical proof is achieved.
Negative Factors
Persistent heavy cash burn
Consistent negative operating and free cash flow forces ongoing external financing, increasing dilution and refinancing risk. Heavy burn constrains strategic flexibility, may delay or cut development programs, and is a durable structural weakness until profitability or sustained positive cash generation is achieved.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused oncology R&D pipeline
A focused oncology R&D strategy targeting radiotherapy enhancement is a durable business-model strength: it concentrates scientific expertise, can create high barriers to entry, and aligns with enduring unmet needs in cancer care. Success can yield licensing, partnerships and durable revenue streams if clinical proof is achieved.
Read all positive factors
Noxopharm Ltd. (NOX) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$24.58M
Dividend YieldN/A
Average Volume (3M)123.50K
Price to Earnings (P/E)―
Beta (1Y)1.20
Revenue GrowthN/A
EPS Growth-137.97%
CountryAU
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.02
Shares Outstanding307,237,950
10 Day Avg. Volume89,571
30 Day Avg. Volume123,503
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)22.89
Price to Sales (P/S)5.60
P/FCF Ratio-2.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Noxopharm Ltd. Business Overview & Revenue Model
Company Description
Noxopharm Limited is an Australian drug development company with an international reach, focused on pioneering new treatment options for a range of solid tumor cancers and septic shock. Its primary asset, Veyonda, functions as an adjuvant therapy ...
How the Company Makes Money
null...
Noxopharm Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
32
Negative
Cash Flow
20
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.66M | 2.82M | 2.40M | 6.01M | 5.43M | 5.61M |
| Gross Profit | -1.05M | -1.45M | -534.81K | 5.86M | 5.17M | 5.35M |
| EBITDA | -6.14M | -5.38M | -5.95M | -20.85M | -23.70M | -5.85M |
| Net Income | -5.49M | -4.88M | -3.58M | -15.06M | -18.67M | -9.35M |
Balance Sheet | ||||||
| Total Assets | 4.75M | 4.58M | 6.78M | 10.13M | 26.59M | 47.85M |
| Cash, Cash Equivalents and Short-Term Investments | 91.40K | 1.55M | 2.32M | 3.01M | 14.01M | 26.80M |
| Total Debt | 4.25M | 2.48M | 0.00 | 0.00 | 160.62K | 349.31K |
| Total Liabilities | 5.88M | 3.89M | 1.29M | 1.06M | 2.48M | 7.08M |
| Stockholders Equity | -1.13M | 689.96K | 5.50M | 9.07M | 24.12M | 40.78M |
Cash Flow | ||||||
| Free Cash Flow | -7.27M | -5.82M | -684.31K | -10.95M | -13.73M | -8.85M |
| Operating Cash Flow | -7.27M | -5.82M | -684.31K | -10.95M | -13.73M | -8.85M |
| Investing Cash Flow | 2.48M | 2.48M | 0.00 | 123.51K | 0.00 | 225.23K |
| Financing Cash Flow | 3.85M | 2.60M | 0.00 | -178.09K | 975.73K | 28.32M |
Noxopharm Ltd. Technical Analysis
Negative
0.09
Price Trends
0.08
Negative
0.08
Positive
0.08
Positive
Market Momentum
>-0.01
Positive
46.52
Neutral
33.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:NOX, the sentiment is Negative. The current price of 0.09 is above the 20-day moving average (MA) of 0.08, above the 50-day MA of 0.08, and above the 200-day MA of 0.08, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 46.52 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:NOX.
Noxopharm Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | AU$5.68B | -528.97 | -1.72% | ― | 59.13% | -121.52% | |
54 Neutral | AU$90.43M | -8.42 | -62.49% | ― | ― | -13.64% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$24.58M | -4.31 | 2509.60% | ― | ― | -137.97% | |
46 Neutral | AU$981.20M | -9.50 | -59.59% | ― | ― | -70.72% | |
45 Neutral | AU$47.71M | -0.78 | -93.08% | ― | 116.02% | 75.56% | |
42 Neutral | AU$391.16M | -39.00 | -47.44% | ― | ― | -15.48% |
* Healthcare Sector Average
AU:NOX
Noxopharm Ltd.
0.08
-0.03
-26.36%
AU:PTX
Prescient Therapeutics Limited
0.09
0.04
88.89%
AU:TLX
Telix Pharmaceuticals
16.45
-1.29
-7.27%
AU:RAC
Race Oncology Ltd.
2.09
0.90
75.63%
AU:CU6
Clarity Pharmaceuticals Ltd.
2.59
-1.37
-34.60%
AU:RAD
Radiopharm Theranostics Limited
0.01
-0.02
-57.69%
Noxopharm Ltd. Corporate Events
Noxopharm Data Validate TLR8-Targeted Oligonucleotide Cancer Strategy
Aug 3, 2026
Noxopharm has reported new preclinical data showing its synthetic RNA oligonucleotides can convert normally immune-silent cellular RNA into a potent trigger for Toll-like receptor 8, a key immune sensor. In vitro, combining total cellular RNA with...
Noxopharm advances Sofra platform as SOF-SKN nears FDA milestone
Jul 21, 2026
Noxopharm’s June quarter report highlights rapid progress across its Sofra platform, including new oligonucleotides that markedly boost Toll-like receptor 8 activity to enhance standard cancer therapies, positioning the company in a fast-exp...
Noxopharm moves SOF-SKN toward U.S. FDA pathway to boost autoimmune portfolio
Jul 6, 2026
Noxopharm has requested a pre-Investigational New Drug meeting with the U.S. Food and Drug Administration to discuss the clinical development pathway, manufacturing and quality controls for SOF-SKN, its autoimmune disease drug candidate. The meeti...
Noxopharm Sofra Platform Backed in $1m Grant for Childbirth Injury Treatment
Jul 1, 2026
Noxopharm’s strategic partner, Hudson Institute of Medical Research, has secured a $1 million Medical Research Future Fund grant for a three-year project using the company’s Sofra™ oligonucleotide platform to address childbirth-r...
Noxopharm unveils human-like TLR8 model to accelerate cancer immunotherapy program
Jul 1, 2026
Noxopharm has developed an advanced animal model intended to fast-track its immuno-oncology program by overcoming a longstanding obstacle in studying Toll-like receptor 8, a key target in its cancer research. Created in collaboration with the Huds...
Noxopharm Starts SOF-SKN Manufacturing Ahead of Cutaneous Lupus Trial
Jun 8, 2026
Noxopharm has begun manufacturing its SOF-SKN drug candidate to support a planned clinical trial later this year targeting cutaneous lupus erythematosus, a chronic autoimmune skin disease with limited targeted therapies. The manufacturing run, con...
Noxopharm Director Restructures Holding Via Off-Market Share Transfer
Jun 1, 2026
Noxopharm has disclosed a change in director Boris Patkin’s interest in the company’s securities, involving an off-market transfer of 630,000 ordinary fully paid shares. The shares were moved from Patkin’s direct holding to Snowy...
Noxopharm Showcases Potent New TLR8-Based Immuno-Oncology Platform
May 25, 2026
Noxopharm Limited unveiled new data demonstrating how its Sofra technology platform can significantly amplify Toll-like receptor 8 activity, a key immune sensor being targeted in cancer therapy. The company’s proprietary oligonucleotides sho...
Noxopharm Plans CEO Option Grant Tied to Long-Term Share Price Growth
May 8, 2026
Noxopharm Ltd. has notified the ASX of a proposed issue of up to 2 million new options to its chief executive officer, with an exercise price set at a 25% premium and an expiry date of 15 April 2030. The options, forming a new class of securities,...
Noxopharm Taps Novotech to Advance SOF-SKN Toward Key FDA Milestone
May 5, 2026
Noxopharm has engaged global clinical research organisation Novotech to support preparations for a pre-Investigational New Drug meeting with the U.S. Food and Drug Administration for its SOF-SKN candidate, part of the Sofra technology platform. Th...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.